129 related articles for article (PubMed ID: 37924960)
1. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study.
Qurashi I; Chaudhry IB; Khoso AB; Omair Husain M; Hafeez D; Kiran T; Lane S; Naqvi HA; Minhas FA; Tamizuddin Nizami A; Razzaque B; Qambar Bokhari S; Yung AR; Deakin B; Husain N
Brain Behav Immun; 2024 Jan; 115():609-616. PubMed ID: 37924960
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
3. Interventions for prodromal stage of psychosis.
Bosnjak Kuharic D; Kekin I; Hew J; Rojnic Kuzman M; Puljak L
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31689359
[TBL] [Abstract][Full Text] [Related]
4. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
5. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
6. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial.
Deakin B; Suckling J; Barnes TRE; Byrne K; Chaudhry IB; Dazzan P; Drake RJ; Giordano A; Husain N; Jones PB; Joyce E; Knox E; Krynicki C; Lawrie SM; Lewis S; Lisiecka-Ford DM; Nikkheslat N; Pariante CM; Smallman R; Watson A; Williams SCR; Upthegrove R; Dunn G;
Lancet Psychiatry; 2018 Nov; 5(11):885-894. PubMed ID: 30322824
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
[TBL] [Abstract][Full Text] [Related]
8. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.
Rietdijk J; Dragt S; Klaassen R; Ising H; Nieman D; Wunderink L; Delespaul P; Cuijpers P; Linszen D; van der Gaag M
Trials; 2010 Mar; 11():30. PubMed ID: 20307268
[TBL] [Abstract][Full Text] [Related]
9. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
[TBL] [Abstract][Full Text] [Related]
10. The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.
Lisiecka DM; Suckling J; Barnes TR; Chaudhry IB; Dazzan P; Husain N; Jones PB; Joyce EM; Lawrie SM; Upthegrove R; Deakin B
Trials; 2015 Mar; 16():71. PubMed ID: 25886254
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
Föcking M; Dicker P; Lopez LM; Cannon M; Schäfer MR; McGorry PD; Smesny S; Cotter DR; Amminger GP
BMC Psychiatry; 2016 Sep; 16(1):326. PubMed ID: 27650124
[TBL] [Abstract][Full Text] [Related]
12. Social recovery therapy for young people with emerging severe mental illness: the Prodigy RCT.
Fowler D; Berry C; Hodgekins J; Banerjee R; Barton G; Byrne R; Clarke T; Fraser R; Grant K; Greenwood K; Notley C; Parker S; Shepstone L; Wilson J; French P
Health Technol Assess; 2021 Nov; 25(70):1-98. PubMed ID: 34842524
[TBL] [Abstract][Full Text] [Related]
13. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
[TBL] [Abstract][Full Text] [Related]
14. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial.
Waite F; Černis E; Kabir T; Iredale E; Johns L; Maughan D; Diamond R; Seddon R; Williams N; Yu LM; Freeman D;
Lancet Psychiatry; 2023 Sep; 10(9):706-718. PubMed ID: 37562423
[TBL] [Abstract][Full Text] [Related]
15. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP
Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360
[TBL] [Abstract][Full Text] [Related]
16. Early intervention for psychosis.
Marshall M; Rathbone J
Cochrane Database Syst Rev; 2006 Oct; (4):CD004718. PubMed ID: 17054213
[TBL] [Abstract][Full Text] [Related]
17. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
[TBL] [Abstract][Full Text] [Related]
18. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial.
Morrison AP; French P; Stewart SL; Birchwood M; Fowler D; Gumley AI; Jones PB; Bentall RP; Lewis SW; Murray GK; Patterson P; Brunet K; Conroy J; Parker S; Reilly T; Byrne R; Davies LM; Dunn G
BMJ; 2012 Apr; 344():e2233. PubMed ID: 22491790
[TBL] [Abstract][Full Text] [Related]
19. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
